Observatory of the Prescription of Erythropoietin as Treatment of Anemia Induced by Chemotherapy or Allograft Conditioning Among the Patients With a Haematological Malignancy

Inclusion Criteria:

* Age ≥ 18 years.
* Patient with AML de novo or secondary myelodysplasia in Complete Remission (CR) after induction and / or salvage therapy and candidate to receive a consolidation therapy.
* OR Patient with hematologic malignancies (ALL, AML, chronic lymphocytic leukemia, CLL, non-Hodgkin lymphoma, MDS, myeloma, myeloproliferative syndrome) and candidate for blood marrow or stem cell or placental blood transplantation.

Depending on the hematologic malignancy, pre-transplant status of patients included will be the CR, very good partial or partial response.

* Patient with anemia (Hb blood level ≤ 110g / l) induced by consolidation chemotherapy or allograft conditioning (myeloablative or non-myeloablative).
* Patient eligible according to the investigator, to treatment with ESA (evaluation by the investigator of the benefice- risk ratio).
* Written informed consent.

Exclusion Criteria:

* Contraindication to epoetin alfa or epoetin zeta.
* Patient not able to receive adequate antithrombotic prophylaxis.
* Patients who received ESA therapy within 3 weeks prior to inclusion.
* non French-speaking patient
* Patient participating or having participated to a clinical trial evaluating a novel molecule in the 30 days before inclusion.
* pregnant or nursing, woman or woman of childbearing potential without effective contraception